Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene for alcohol-related liver disease (pilot study)
jRCT1031220022Recruiting
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nalmefene in alcoholic liver disease (ALD) and alcohol use disorder (AUD). Primary endpoint: Change in serum GGT at 24 weeks. Started Apr 2022; status: recruiting.
02
Drugs
nalmefene
03
Conditions
alcoholic liver disease (ALD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on jRCT1031220022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220022.